Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3365-3372

  Rubino, C M ^a   Bhavnani, S M ^a   Moeck, G ^b   Bellibas, S E ^b   Ambrose, P G ^a  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b MEDICINES COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORITAVANCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; GLYCOPEPTIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIAL SKIN DISEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VERY ELDERLY; VOLUME OF DISTRIBUTION; ADOLESCENT; CLINICAL TRIAL; MIDDLE AGED; MONTE CARLO METHOD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; GLYCOPEPTIDES; HUMANS; MIDDLE AGED; MONTE CARLO METHOD; YOUNG ADULT;

EID: 84929650016     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00176-15     Document Type: Article

References (22)

1. Mendes RE, Farrell DJ, Sader HS, Jones RN. 2012. Oritavancin microbiologic features and activity results from the surveillance program in the United States. Clin Infect Dis 54Suppl 3):S203-S213. http://dx.doi.org/10.1093/cid/cir923.
2. Arhin FF, Sarmiento I, Moeck, G. 2014. In vitro activities of oritavancin and comparators against methicillin-resistant Staphylococcus aureus isolates harboring the novel mecC gene. Int J Antimicrob Agents 44:65-68. http://dx.doi.org/10.1016/j.ijantimicag.2014.03.015.
3. The Medicines Company. 2014. Orbactiv (oritavancin) for injection. Prescribing information. The Medicines Company, Parsippany, NJ.
4. Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, Giordano P, Lucasti C, Perex A, Good S, Jiang H, Moeck G, O'Riorday W. 2014. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 370:2180-2190. http://dx.doi.org/10.1056/NEJMoa1310422.
5. Corey GR, Good S, Jiang H, Moeck G, Wilker M, Green S, Manos P, Keech R, Singh R, Heller B, Bubnova N, O'Riorday W. 2015. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of Gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis 60:254-262. http://dx.doi.org/10.1093/cid/ciu778.
6. Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollum JS, Forrest A. 2009. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother 53:4422-4428. http://dx.doi.org/10.1128/AAC.00231-09.
7. Gehan EA, George SL. 1970. Estimation of human body surface area from height and weight. Cancer Chemother Rep 54:225-235.
8. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. http://dx.doi.org/10.1159/000180580.
9. U.S. Food and Drug Administration. 1999. Guidance for industry on population pharmacokinetics; availability. Fed Regist 64:6663-6664.
10. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481-504. http://dx.doi.org/10.1023/A:1012299115260.
11. Bauer RJ. 2006. S-ADAPT/MCPEM user's guide: software for pharmacokinetic, pharmacodynamic and population data analysis. University of Southern California, Los Angeles, CA.
12. D'Argenio DZ, Schumitzky A. 1979. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9:115-134. http://dx.doi.org/10.1016/0010-468X(79)90025-4.
13. D'Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
14. Akaike H. 1979. Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 66:237-242. http://dx.doi.org/10.1093/biomet/66.2.237.
15. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143-151. http://dx.doi.org/10.1208/s12248-011-9255-z.
16. Bhavnani SM, Hammel JP, Rubino CM, Moeck G, Jiang H, Bellibas SE, Ambrose PG. 2014. Oritavancin pharmacokinetic-pharmacodynamic analyses for efficacy based on data from patients with acute bacterial skin and skin structure infections enrolled in SOLO I and II, abstr A-1309. Abstr 54th Intersci Conf Antimicrob Agents Chemother, Washington, DC, 5 to 9 September 2014.
17. Okusanya OO, Lehoux D, Forrest A, Moeck G, Bulik CC, Ambrose PG, Bhavnani SM. 2012. Pharmacokinetic-pharmacodynamic evaluation of oritavancin against Staphylococcus aureus using data from a murine-thigh infection model, abstr A-620. Abstr 52nd Intersci Conf Antimicrob Agents Chemother, San Francisco, CA, 9 to 12 September 2012.
18. Okusanya OO, Lehoux D, Van Wart SA, Deng H, Forrest A, Rafai Far A, Moeck G, Bhavnani SM, Ambrose PG, Parr TR, Jr. 2009. Pharmacokinetics and pharmacokinetics-pharmacodynamics of oritavancin against Streptococcus pyogenes using data from a neutropenic murine thigh-infection model, abstr A1-1286. Abstr 49th Intersci Conf Antimicrob Agents Chemother, San Francisco, CA, 12 to 15 September 2009.
19. Gibaldi M, Perrier D. 1975. Pharmacokinetics, p 45-96. Marcel Dekker, Inc., New York, NY.
20. Van Wart SA, Owen JS, Ludwig EA, Meagher AK, Korth-Bradley JM, Cirincione BB. 2006. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob Agents Chemother 50:3701-3707. http://dx.doi.org/10.1128/AAC.01636-05.
21. Moore KHP, Yuen GJ, Hussey EK, Pakes GE, Eron JJ, Bartlett JA. 1999. Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother 43:3023-3029.
22. Ambrose PG, Drusano GL, Craig WA. 2012. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis 54(Suppl 3):S220-S228. http://dx.doi.org/10.1093/cid/cis001.